ArticlePakistan journal of medical sciences2026
Efficacy of Huoxue Tongqiao Decoction combined with aniracetam in treating post-stroke cognitive impairment in elderly patients with ischemic stroke and its effects on serum levels of superoxide dismutase, glutathione peroxidase and nitric oxide.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the clinical efficacy of Huoxue Tongqiao (blood-invigorating and orifice-unblocking) Decoction (HXTQD) combined with aniracetam in the treatment of post-ischemic stroke cognitive impairment (PISCI) in elderly patients and its effects on related serum biochemical markers. Methodology: This was a retrospective study. A total of 80 elderly patients with PSCI admitted to Baoding No.1 Central Hospital between January 2022 to December 2024 were enrolled and randomly assigned to either the control group or the observation group using a random number table. All patients received standard internal medicine management. The control group was treated with aniracetam, while the observation group was orally administered HXTQD in combination with aniracetam. TCM syndrome, MoCA, MMSE, ADL scores, cerebral hemodynamic parameters and serum biochemical markers were assessed before and after treatment. The overall response rate was compared between the two groups. Results: After treatment, both groups showed significant improvements in MoCA, MMSE and ADL scores, Vm and serum levels of SOD, GSH-Px and NO(all P< 0.05), with the observation group demonstrating significantly greater improvements than the control group (P< 0.05). TCM syndrome scores, RI and PI decreased in both groups, with more pronounced reductions noted in the observation group (P< 0.05, respectively). The ORR in the observation group was significantly higher than in the control group (P< 0.05). No adverse reactions were reported in either group. Conclusion: The combination of HXTQD and aniracetam can significantly improve cognitive function and cerebral perfusion in elderly patients with post-ischemic stroke cognitive impairment, potentially by regulating serum SOD, GSH-Px and NO levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.